| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.38 | 7e-12 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.31 | 2e-08 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.23 | 3e-08 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.25 | 4e-08 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | 0.21 | 9e-07 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.18 | 1e-06 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.21 | 1e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.27 | 2e-06 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.2 | 2e-06 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.29 | 3e-06 |